Objective: To study the efficacy of bovine colostrum in prevention of necrotizing enterocolitis (NEC) and sepsis in very low birth weight (VLBW) infants.
I N T R O D U C T I O N
Necrotizing enterocolitis (NEC) primarily occurs in premature and very low birth weight (VLBW) babies, the incidence varying from 5 to 10% in various neonatal intensive care unit (NICUs) [1] . Many researchers believe that an exaggerated inflammatory response mounted by immature intestinal epithelial cells in response to abnormal intestinal colonization plays a vital role in the pathogenesis of NEC [2] [3] [4] , and bacteria belonging to Enterobacteriaceae have often been linked to NEC [5] [6] [7] . Colonization with commensal bacteria soon after birth is essential for the development of normal intestinal function [8] ; however, this process is often altered in premature babies in NICUs, leading to colonization with pathogenic bacteria [8, 9] .
The use of human milk has been consistently shown to reduce the incidence of NEC and sepsis [10] . Immunoglobulins in human milk reduce the adherence of pathogenic bacteria to the gut epithelium and thus decrease colonization by such bacteria [11] . Other anti-infective factors and growth factors in human milk are also believed to play an important role. However, the use of exogenous oral immunoglobulins has not been shown to reduce NEC or sepsis [12] . A possible reason could be that antiinfective factors act in synergy and a single agent may not be effective. Commercially available bovine colostrum has high concentrations of anti-infective factors such as immunoglobulins, lactoferrin, organism-specific antibodies, lactoperoxidase, insulin-like growth factors and transforming growth factors. These components have substantial homology to their human counterparts [13] . Bovine colostrum has been tried in the treatment of Escherichia coli [14] and Shigella [15] and Rotavirus diarrhea [16, 17] in children, Helicobacter pylori [16] infection in children and E. coli [18] intestinal infection in term and preterm neonates. No major adverse effects were reported in any of the studies using bovine colostrum in infants and preterm babies [19] [20] [21] . In an in vitro study, the authors showed that bovine colostrum significantly reduces the adherence of various Enterobacteriaceae species-known to be associated with NEC-to human intestinal epithelial cells [22] . A randomized controlled trial has shown that the use of bovine lactoferrin reduced the incidence of neonatal sepsis [23] . Till date, there are no studies in neonates on the use of bovine colostrum for the prevention of NEC.
In view of the above observations, we hypothesized that bovine colostrum, which is a naturally occurring complex mixture of several anti-infective factors, could prevent NEC and sepsis.
M A T E R I A L S A N D M E T H O D S
This was a blinded, parallel-group, stratified, blockrandomized, placebo-controlled trial conducted at a level III NICU in Northern India. We included babies with birth weight 1500 g and gestational age 32 completed weeks and chronological age 96 hours. We excluded those babies who had any contraindication for initiating milk feeds; who failed to achieve adequate feed volume to be able to administer the study drug; or those with suspected/ proven gastrointestinal malformations or preexisting sepsis (definite or suspect) or NEC at the time of enrollment; or those with a family history of an inborn error of metabolism (that precludes exposure to proteins/lactose).
The study protocol was approved by the Institute Ethics Committee, and all the babies were included after getting written informed consent from the parents.
The subjects were randomly allocated immediately after written informed consent was obtained. It was a stratified block-randomized design, with a 1:1 allocation ratio. We stratified subjects according to birth weight (<1000 g and 1000 g). One of the investigators Standard Deviation (SD), generated randomly varying, permuted, even-numbered blocks and the randomization sequence from a Web site (www.randomization.com). Subjects were allocated to receive either prophylactic bovine colostrum or placebo.
Interventions
The neonates in the bovine colostrum group received PedimmuneV R (Merk India Ltd., Mumbai, India), which was administered in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever was earlier. The required amount was supplied in a sachet. A nurse mixed the powder in expressed human milk (with 2 ml for <1 kg stratum and with 3 ml for >1 kg stratum) and administered it through an oro-gastric tube. We derived these doses from previous studies on oral IgG for the prevention of NEC. We calculated the bovine colostrum dose that would provide 400 mg/kg/day of the IgG component (3 g of PedimmuneV R contains 175 mg of IgG). The manufacturer of the product did not endorse the study in any way.
Subjects in the control group received an equal dose of placebo, which was identical in physical appearance and miscibility to bovine colostrum. The bovine colostrum and the placebo sachets were provided in identical bottles. The parents, doctors, nurses, laboratory staff and the investigator measuring the outcome were blinded. To conceal allocation, the bottles were serially numbered on the outside, based on the random sequence.
Monitoring and follow-up
We actively monitored the subjects for development of clinical features of NEC and sepsis, based on an objective, predefined repertoire of clinical signs that was recorded daily. Subjects who were suspected to have NEC (based on clinical features) underwent an abdominal X-ray and stool occult blood assay. Subjects who were suspected to have sepsis underwent a blood culture, a sepsis screen [C Reactive protein (CRP), total leucocyte count, absolute neutrophil count, micro erythrocyte sedimentation rate] using standard procedures. A stool sample was collected 72 h after starting the study drug/placebo. It was assayed for interleukin-6 (IL-6). The episodes of sepsis and NEC were managed according to the standard unit protocols.
The diagnosis and classification of NEC were made according to Bell staging criteria with the Walsh and Kleigman modification [24] . Stage 1 was considered as suspect NEC, and stages 2 and 3 as definite NEC. Definite sepsis was diagnosed if there were clinical signs of sepsis with a positive blood culture or positive culture from any otherwise sterile body site. Suspected sepsis was defined as the presence of clinical signs of sepsis with sepsis screen positive (defined as CRP >10 mg/l or any two parameters positive) or chest X-ray suggestive of pneumonia and sterile cultures.
There were no changes in feeding practices and other clinical practices related to NEC during the duration of the study. Probiotics and acid suppressing medications were not used. The use of fresh human milk was strongly encouraged and was part of routine unit policy.
The primary outcome was definite NEC, and the secondary outcomes included 'definite or probable NEC', definite sepsis, 'definite or probable sepsis', mortality, a composite of definite sepsis/NEC or death and IL-6 levels in the 72 h stool sample. The secondary outcomes were defined a priori.
We recruited an arbitrary sample of 86 subjects. This was based on the feasibility of recruiting subjects within the time frame available to us within the limitations of a single-center pilot study.
Descriptive statistics was used for describing baseline variables. Dichotomous outcomes were compared by Chi square test with continuity correction or Fisher's Exact test as applicable. Numerical variables were compared by Student's t-test or Mann Whitney U-test, depending on distribution. Analysis was intention to treat, i.e. all subjects who are randomized were included in analysis, irrespective of degree of compliance. Analysis was done using Statistical Product and Service Solutions (SPSS) version 13 (2005, USA).
R E S U L T S
Of 160 subjects who met inclusion criteria, 74 were excluded on the basis of various exclusion criteria and non-availability of parental consent (Figure 1 ). The baseline variables (Table 1) [14.0, 19.5] in the colostrum and placebo groups, respectively (p < 0.05). There were no statistically significant differences in any of the important outcomes between the two groups ( Table 2 ). The incidence of definite NEC was 9.3% and 2.3% in the bovine colostrum group and placebo groups, respectively [relative risk (RR) ¼ 4.31; 95% confidence interval (CI) ¼ 0.42, 105.82; p-value ¼ 0.4]. The incidence of the composite outcome of 'definite sepsis or definite NEC or mortality' was 25.6% and 27.9% in the two groups, respectively [RR ¼ 0.92; 95% CI ¼ 0.46, 1.85; p-value ¼ 0.8]. Similarly, there were no statistically significant differences in the incidence of any NEC, definite sepsis, any sepsis, death or the composite of 'any sepsis or any NEC or mortality'.
The clinical signs of sepsis and NEC were comparable between the colostrum and placebo group ( Table 3) . The radiological signs suggestive of NEC showed a trend toward a higher incidence in the colostrum group. Bowel wall edema and fixed bowel loops were each found in six babies in the colostrum group and one each in the placebo group (p ¼ 0.1 for both findings). Pneumatosis intestinalis was noticed in six patients, of which five were in the colostrum group (p ¼ 0.2). Pneumoperitoneum was present in two babies, both of whom belonged to the colostrum group.
The mean level of IL-6 in stool was higher in the colostrum group [15.07 pg/ml (SD ¼ 42.9)] compared with the placebo group [0.62 pg/ml (SD ¼ 2.31)] but this difference fell short of statistical significance (p ¼ 0.07).
D I S C U S S I O N
Our study showed no significant differences in the occurrence of NEC, sepsis or mortality after the administration of bovine colostrum, when compared with placebo. Contrary to our hypothesis, there was a trend toward higher stool IL-6 levels and increased incidence of radiological features of NEC in the group that received bovine colostrum.
We conducted this study among premature VLBW babies because these are the most important identifiable risk factors for the development of NEC. A cutoff postnatal age <96 h was implemented with the hope of providing the intervention before abnormal colonization and inflammation could start. Ours was a double-blind, randomized, placebo-controlled trial with adequate concealment of allocation and complete follow-up. Randomization was successful in balancing known baseline demographic variables and risk factors for sepsis and NEC between the two groups. There is no study in the published literature on the use of bovine colostrum in the neonatal age group for the prevention of NEC and sepsis. The closest available studies are those that used oral immunoglobulins [12, [25] [26] [27] or bovine lactoferrin by Manzoni [23] in neonates. We hypothesized that it would be preferable to use bovine colostrum rather than immunoglobulins or lactoferrin, as colostrum is a naturally occurring balanced product and apart from IgG it contains many other active and potentially beneficial components, like growth factors and cytokines [28] [29] [30] . All these have cytoprotective and immunomodulatory actions and can potentially prevent injury to the neonatal intestine. So we expected that using the whole bovine would increase the probability of a potentially favorable outcome.
The unexpected finding from our study was that there was a trend toward higher stool IL-6 values in the bovine colostrum group. There was also a trend toward a higher incidence of ileus and radiological signs of NEC in the bovine colostrum group.
In an in vitro study, HJL Brooks et al. [22] demonstrated that incubation with bovine colostrum significantly reduced the adherence of isolates of Enterobacteriaceae to colonic cells. The fact that we could not reproduce this result in the form of a reduction in NEC or sepsis suggests that these are complex disease processes that are influenced by several predisposing factors, other than just bacterial colonization. We did not study colonization patterns, for logistic reasons. The Cochrane review of the studies on oral immunoglobulin [12] showed a trend toward reduction of NEC in the study, which used a mixture of IgA and IgG. In the Randomized Controlled Trial (RCT), by Manzoni et al. [23] , the incidence of lateonset sepsis and definite NEC was significantly lower in the group that received bovine lactoferrin. The reason behind the unexpected trends in our study could be that bovine colostrum (which contains many proteins other than immunoglobulins and lactoferrin) may have caused increased intestinal inflammation. This may have overshadowed any putative benefits provided by anti-infective factors. Thus, the safety of the product in neonates could not be established by our study. Investigators evaluating bovine colostrum in neonates in future trials should be cautious and keep in mind that bovine colostrum may increase intestinal inflammation.
Clinical practices that are related to NEC were largely static in our unit during the study period. Probiotics were not used in our unit. Human milk feeding is actively promoted in our unit, and barring exceptional circumstances, all VLBW babies are started on human milk feeds.
The main limitation of our study was its small sample size. For financial reasons, we were unable to measure the osmolality of the reconstituted colostrum or placebo preparations. Increased osmolality may have been a contributory factor for the trend toward intestinal inflammation. A few studies published in the 1970s [31, 32] had suggested a link between high osmolality and NEC, but none of them were able to prove the association with hyperosmolar feeds in a methodologically sound manner. In Santulli's study, the term infants who developed NEC had received a hyperosmolar formula, which in that era had an osmolarity of 750 mosm/l [31] . In Book's study, there was a background incidence of NEC of 27% and the hypertonic formula incriminated in NEC had an osmolarity of 650 mosm/l [32] . As it was a small pilot study, we did not have provision for an interim analysis for harm. Future studies should ideally include an assessment of osmolality.
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